Edition:
United Kingdom

Pharmaceuticals

Page 1

Teva Announces Launch Of A Generic Version Of Tracleer® (Bosentan) Tablets In The United States

Wednesday, 19 Jun 2019

Teva Pharmaceutical Industries Ltd ::TEVA ANNOUNCES LAUNCH OF A GENERIC VERSION OF TRACLEER® (BOSENTAN) TABLETS IN THE UNITED STATES.TEVA PHARMACEUTICAL INDUSTRIES LTD - ANNOUNCED LAUNCH OF A GENERIC VERSION OF TRACLEER(®1) (BOSENTAN) TABLETS, 62.5 MG AND 125 MG, IN U.S..

Merck Prepares For CEO's Departure With Internal Successor Hunt - Bloomberg

Wednesday, 19 Jun 2019

June 19 (Reuters) - :MERCK PREPARES FOR CEO'S DEPARTURE WITH INTERNAL SUCCESSOR HUNT - BLOOMBERG.

Faes Farma To Pay A Total Dividend Of 0.14 EUR/Shr

Wednesday, 19 Jun 2019

June 19 (Reuters) - Faes Farma SA ::TO PAY A TOTAL DIVIDEND OF 0.14 EUROS PER SHARE.SEES 2019 NET PROFIT TO RISE BETWEEN +16% AND +22% (TO 60 MILLION - 63 MILLION EUROS) AND REVENUE TO +8.8%/+10% (TO 353 MILLION - 356 MILLION EUROS).

Sophiris Bio Receives Positive Feedback From European Medicines Agency Regarding Phase 3 Localized Prostate Cancer Clinical Trial Design

Wednesday, 19 Jun 2019

June 19 (Reuters) - Sophiris Bio Inc ::SOPHIRIS BIO RECEIVES POSITIVE FEEDBACK FROM EUROPEAN MEDICINES AGENCY REGARDING PHASE 3 LOCALIZED PROSTATE CANCER CLINICAL TRIAL DESIGN.SOPHIRIS BIO INC - PHASE 3 STUDY DESIGN, AGREED UPON BY EMA, WILL ENROLL PATIENTS WITH A CONFIRMED DIAGNOSIS OF INTERMEDIATE RISK DISEASE..SOPHIRIS BIO - BELIEVE THAT DATA FROM A SINGLE PHASE 3 TRIAL, IF SUCCESSFUL, WILL BE SUFFICIENT TO SUPPORT MARKET APPROVAL IN EUROPE.

CannTrust Says Establishing Operations In U.S

Wednesday, 19 Jun 2019

June 19 (Reuters) - CannTrust Holdings Inc ::CANNTRUST ESTABLISHES U.S. OPERATIONS.CANNTRUST - SIGNED LOI THAT WILL PROVIDE ACCESS TO OVER 3,000 ACRES OF FARMLAND FOR HEMP PRODUCTION WITH ELK GROVE FARMING COMPANY.CANNTRUST HOLDINGS - ESTABLISHING OPERATIONS IN U.S., STARTING IN STATE OF CALIFORNIA.CANNTRUST HOLDINGS INC - CO, ELK GROVE WILL EACH HAVE 50% OWNERSHIP OF A NEW ENTITY.CANNTRUST - INVESTMENT IN U.S. OPERATION IS EXPECTED TO BE UP TO $20 MILLION THROUGH TO END OF 2020.CANNTRUST - BOTH PARTIES WILL PROVIDE EQUAL CONTRIBUTION OF CAPITAL TO FINANCE OPERATIONS OF JV.

Astrazeneca And Merck's Lynparza Approved In Japan

Wednesday, 19 Jun 2019

June 19 (Reuters) - Merck & Co Inc ::ASTRAZENECA AND MERCK’S LYNPARZA® (OLAPARIB) APPROVED IN JAPAN AS FIRST-LINE MAINTENANCE THERAPY IN PATIENTS WITH BRCA-MUTATED ADVANCED OVARIAN CANCER.MERCK & CO - JAPAN'S PHARMACEUTICALS AND MEDICAL DEVICES AGENCY (PMDA) HAS APPROVED LYNPARZA AS A MAINTENANCE TREATMENT AFTER FIRST-LINE CHEMOTHERAPY.MERCK & CO INC - LYNPARZA APPROVAL IN JAPAN WAS BASED ON DATA FROM RANDOMIZED, DOUBLE-BLINDED PHASE 3 SOLO-1 TRIAL.

Astrazeneca And Merck's Lynparza Approved In Japan

Wednesday, 19 Jun 2019

June 19 (Reuters) - Merck & Co Inc ::ASTRAZENECA AND MERCK’S LYNPARZA® (OLAPARIB) APPROVED IN JAPAN AS FIRST-LINE MAINTENANCE THERAPY IN PATIENTS WITH BRCA-MUTATED ADVANCED OVARIAN CANCER.MERCK & CO - JAPAN'S PHARMACEUTICALS AND MEDICAL DEVICES AGENCY (PMDA) HAS APPROVED LYNPARZA AS A MAINTENANCE TREATMENT AFTER FIRST-LINE CHEMOTHERAPY.MERCK & CO INC - LYNPARZA APPROVAL IN JAPAN WAS BASED ON DATA FROM RANDOMIZED, DOUBLE-BLINDED PHASE 3 SOLO-1 TRIAL.

Amphastar Pharmaceuticals Announces Settlement In Litigation With Momenta And Sandoz

Wednesday, 19 Jun 2019

June 19 (Reuters) - Amphastar Pharmaceuticals Inc ::AMPHASTAR PHARMACEUTICALS, INC. ANNOUNCES SETTLEMENT IN LITIGATION WITH MOMENTA AND SANDOZ.AMPHASTAR PHARMACEUTICALS - MOMENTA/SANDOZ WILL PAY CO $59.9 MILLION NO LATER THAN JULY 2.AMPHASTAR PHARMACEUTICALS INC - CO, MOMENTA/SANDOZ WILL SUBMIT STIPULATIONS OF DISMISSAL OF ALL PENDING LITIGATION BETWEEN PARTIES..

Amphastar Pharmaceuticals Announces Settlement In Litigation With Momenta And Sandoz

Wednesday, 19 Jun 2019

June 19 (Reuters) - Amphastar Pharmaceuticals Inc ::AMPHASTAR PHARMACEUTICALS, INC. ANNOUNCES SETTLEMENT IN LITIGATION WITH MOMENTA AND SANDOZ.AMPHASTAR PHARMACEUTICALS - MOMENTA/SANDOZ WILL PAY CO $59.9 MILLION NO LATER THAN JULY 2.AMPHASTAR PHARMACEUTICALS INC - CO, MOMENTA/SANDOZ WILL SUBMIT STIPULATIONS OF DISMISSAL OF ALL PENDING LITIGATION BETWEEN PARTIES..

Sihuan Pharmaceutical Holdings Says Co Granted Drug Registration Approval

Wednesday, 19 Jun 2019

June 19 (Reuters) - Sihuan Pharmaceutical Holdings Group Ltd <0460.HK>::GRANTED DRUG REGISTRATION APPROVAL FOR SOLID-LIQUID DOUBLE CHAMBER BAG.APPROVAL GRANTED BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF PRC.

Markets

  • Sectors
  • Europe
  • U.S.
  • Asia

Sector Summary